Joseph A. Madri, Ph.D., M.D.
Dr. Madri is a Professor of Pathology at Yale University School of Medicine and founder of Alexion Inc. Dr. Madri brings to Neutrolis extensive expertise and experience of building a preeminent drug discovery and development organization from the earliest stages through launch of multiple commercial products.
Kaplan J. Mariana., M.D.
Dr. Kaplan is Senior Investigator and Chief of Systemic Autoimmunity Branch and Acting Director of Lupus Clinical Trial Unit at National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). She is a key opinion leader and her research focuses on identifying abnormalities of neutrophil subset and the role of NETs in lupus and rheumatoid arthritis and other systemic autoimmune disease. Dr. Kaplan advices Neutrolis on novel NET based lupus biomarkers and also clinical trial strategy for lupus and RA.
Karen Costenbader, MD, MPH
Dr. Costenbader is the Director of the lupus program at Brigham and Women’s Hospital in Boston and Professor of Medicine at Harvard Medical School. She is also the Chair of the Medical-Scientific Advisory Council for Lupus Foundation of America. Dr. Costenbader advises Neutrolis on the clinical trial feasibility for lupus and is a collaborator on the NIH-SBIR grant that Neutrolis received to identify biomarkers for lupus therapy.
Reinhard Voll, M.D.
Dr. Voll is the Director of the Department of Rheumatology at the University of Freiburg and brings to Neutrolis extensive clinical expertise in autoimmune disorders and collaborates on identifying and validating biomarkers for lupus.
Mark Looney, MD
Dr. Looney is a Professor of Medicine and Laboratory Medicine and Attending Physician on the Pulmonary Consult Service and the Intensive Care Units at UCSF. Dr. Looney advises Neutrolis on Acute Respiratory Distress Syndrome (ARDS) program and he is also the collaborator on the NIH-SBIR grant that Neutrolis received for developing therapies that target NETs in ARDS.
Denisa Wagner, Ph.D.
Dr. Denisa Wager is a professor of medicine at Harvard Medical School, a senior investigator in the Program in Cellular and Molecular Medicine, and a member of the Division of Hematology/Oncology at Boston Children's Hospital.
Dr. Wagner is a key opinion leader in the field of NETs with #XXX publications in this space. She brings deep understanding of vascular biology, adhesion molecules and inflammatory pathways to Neutrolis and is a co-inventor on core aspects of Neutrolis’s proprietary technology.
Her research efforts have uncovered foundational aspects of how pathogenic NETs influence both acute and chronic disorders in humans. These disorders include (thrombosis, atherosclerosis, reperfusion injury, wound healing, cancer associated thrombosis, stroke and ALI.